Therapeutic areas

Cancer remains one of the most challenging diseases, accounting for nearly 10 million deaths worldwide in 2022 according to the World Health Organization. Understanding the complexities of this multifaceted disease, BioNTech has built a diversified preclinical and clinical portfolio to address the full continuum of cancer.

Infectious diseases remain among the leading causes of death and disability worldwide, posing a significant threat to global health. These diseases, caused by pathogens ranging from respiratory viruses to bacteria and parasites, require innovative solutions to mitigate their impact. BioNTech is committed to advancing its infectious disease programs through the development of mRNA- as well as protein-based vaccines and therapeutics.